443 related articles for article (PubMed ID: 24118514)
1. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
[TBL] [Abstract][Full Text] [Related]
2. A large-scale computational study of inhibitor risk in non-severe haemophilia A.
Shepherd AJ; Skelton S; Sansom CE; Gomez K; Moss DS; Hart DP
Br J Haematol; 2015 Feb; 168(3):413-20. PubMed ID: 25244644
[TBL] [Abstract][Full Text] [Related]
3. FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.
Hart DP
Front Immunol; 2020; 11():1498. PubMed ID: 32849511
[TBL] [Abstract][Full Text] [Related]
4. Significance of F8 missense mutations with respect to inhibitor formation.
Schwaab R; Pavlova A; Albert T; Caspers M; Oldenburg J
Thromb Haemost; 2013 Mar; 109(3):464-70. PubMed ID: 23306409
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.
Jacquemin M; Vantomme V; Buhot C; Lavend'homme R; Burny W; Demotte N; Chaux P; Peerlinck K; Vermylen J; Maillere B; van der Bruggen P; Saint-Remy JM
Blood; 2003 Feb; 101(4):1351-8. PubMed ID: 12393451
[TBL] [Abstract][Full Text] [Related]
6. Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.
Pinto P; Ghosh K; Shetty S
Blood Cells Mol Dis; 2014 Sep; 53(3):161-3. PubMed ID: 24824129
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A.
Hart DP; Uzun N; Skelton S; Kakoschke A; Househam J; Moss DS; Shepherd AJ
Haematologica; 2019 Mar; 104(3):599-608. PubMed ID: 30266735
[TBL] [Abstract][Full Text] [Related]
8. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
9. HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study.
Kempton CL; Payne AB
Blood Adv; 2018 Jul; 2(14):1750-1755. PubMed ID: 30037801
[TBL] [Abstract][Full Text] [Related]
10. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
[TBL] [Abstract][Full Text] [Related]
11. Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil.
De Barros MF; Herrero JC; Sell AM; De Melo FC; Braga MA; Pelissari CB; Machado J; De Souza Schiller S; De Souza Hirle L; Visentainer JE
Haemophilia; 2012 May; 18(3):e236-40. PubMed ID: 21726358
[TBL] [Abstract][Full Text] [Related]
12. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor development in correlation to factor VIII genotypes.
Oldenburg J; El-Maarri O; Schwaab R
Haemophilia; 2002 Mar; 8 Suppl 2():23-9. PubMed ID: 11966849
[TBL] [Abstract][Full Text] [Related]
14. Computational modelling and inhibitor risk: predicting the future?
Hart DP
Haemophilia; 2014 Mar; 20(2):155-7. PubMed ID: 24393500
[No Abstract] [Full Text] [Related]
15. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.
James EA; van Haren SD; Ettinger RA; Fijnvandraat K; Liberman JA; Kwok WW; Voorberg J; Pratt KP
J Thromb Haemost; 2011 Apr; 9(4):689-99. PubMed ID: 21251204
[TBL] [Abstract][Full Text] [Related]
16. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
[TBL] [Abstract][Full Text] [Related]
17. Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation.
Zimmermann MA; Oldenburg J; Müller CR; Rost S
Haemophilia; 2014 May; 20(3):e215-21. PubMed ID: 24602271
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.
Pandey GS; Yanover C; Howard TE; Sauna ZE
PLoS Comput Biol; 2013; 9(5):e1003066. PubMed ID: 23696725
[TBL] [Abstract][Full Text] [Related]
19. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.
Jones TD; Phillips WJ; Smith BJ; Bamford CA; Nayee PD; Baglin TP; Gaston JS; Baker MP
J Thromb Haemost; 2005 May; 3(5):991-1000. PubMed ID: 15869596
[TBL] [Abstract][Full Text] [Related]
20. Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A.
Pergantou H; Varela I; Moraloglou O; Economou M; Spanou K; Kapsimali Z; Constantinidou N; Platokouki H
Haemophilia; 2013 Sep; 19(5):706-10. PubMed ID: 23607306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
